
| Impact of the COVID-19 pandemic on clinical trials with drugs #MMPMID32970481Hasford JExpert Opin Drug Saf 2020[Nov]; 19 (11): 1373-1375 PMID32970481show ga
?|*Coronavirus Infections/diagnosis/epidemiology/therapy/transmission[MESH]|*Pandemics[MESH]|*Pneumonia, Viral/diagnosis/epidemiology/therapy/transmission[MESH]|*Research Design[MESH]|COVID-19[MESH]|Clinical Trials as Topic/*organization & administration[MESH]|Delivery of Health Care, Integrated/*organization & administration[MESH]|Humans[MESH]|Infection Control/*organization & administration[MESH]|Infectious Disease Transmission, Patient-to-Professional/prevention & control[MESH]|Infectious Disease Transmission, Professional-to-Patient/prevention & control[MESH]|Occupational Health[MESH]|Patient Safety[MESH]|Psychological Distance[MESH]|Research Personnel/*organization & administration[MESH]
  
DeepDyve Pubget Overpricing | 
|